SuperworthInovio Pharmaceuticals revenue INO
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0
- Latest quarter, Q2 FY26
- $0
- Fiscal year 2025
- $65.3K
- −70% on the year before
Inovio Pharmaceuticals' revenue was $0 over the twelve months to Jun 30, 2026, down 100% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $65.3K | −70% |
| FY2024 | $217.8K | −74% |
| FY2023 | $832K | −92% |
| FY2022 | $10.3M | +478% |
| FY2021 | $1.8M | −76% |
| FY2020 | $7.4M | +80% |
| FY2019 | $4.1M | −87% |
| FY2018 | $30.5M | −28% |
| FY2017 | $42.2M | +19% |
| FY2016 | $35.4M | −13% |
| FY2015 | $40.6M | +288% |
| FY2014 | $10.5M | −22% |
| FY2013 | $13.5M | +227% |
| FY2012 | $4.1M | −58% |
| FY2011 | $9.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0 | n/a | $0 | |
| Q1 FY26 | $0 | −100% | $0 | |
| Q4 FY25 | $0 | −100% | $65.3K | |
| Q3 FY25 | $0 | n/a | $182.3K | |
| Q2 FY25 | $0 | −100% | $182.3K | |
| Q1 FY25 | $65.3K | n/a | $283.1K | |
| Q4 FY24 | $117K | +14% | $217.8K | |
| Q3 FY24 | $0 | −100% | $203.4K | |
| Q2 FY24 | $100.8K | −55% | $591.9K | |
| Q1 FY24 | $0 | −100% | $717.1K | |
| Q4 FY23 | $102.7K | −18% | $832K | |
| Q3 FY23 | $388.4K | −96% | $854K |
Against its peers
Companies in Drug Manufacturers - General nearest Inovio Pharmaceuticals' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| INOInovio Pharmaceuticals | $0 | −100% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| Peer median | $316.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Inovio Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.